Ani Pharmaceuticals (ANIP) Cash from Financing Activities (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$21.6 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$21.6 million, down 118.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$21.7 million (down 107.88% YoY), and the FY2025 annual result was -$9.9 million, down 103.75% from the prior year.
• Cash from Financing Activities came in at -$21.6 million for Q1 2026 at Ani Pharmaceuticals, down from -$4.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $291.0 million in Q3 2024 to a low of -$21.6 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$1.7 million (2025), against an average of $17.4 million.
• Across the five-year window, Cash from Financing Activities sank 2246.06% in 2023 and jumped 7650.47% in 2024, its largest moves.
• Ani Pharmaceuticals' Cash from Financing Activities stood at -$508000.0 in 2022, then tumbled by 2246.06% to -$11.9 million in 2023, then soared by 58.83% to -$4.9 million in 2024, then rose by 5.52% to -$4.6 million in 2025, then plunged by 366.26% to -$21.6 million in 2026.
• The last three Cash from Financing Activities figures came in at -$21.6 million (Q1 2026), -$4.6 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.